Sign up to access all valuation multiples
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
1970
1.1K+
LTM Revenue $257M
LTM EBITDA $45.1M
$525M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lumibird has a last 12-month revenue (LTM) of $257M and a last 12-month EBITDA of $45.1M.
In the most recent fiscal year, Lumibird achieved revenue of $244M and an EBITDA of $36.1M.
Lumibird expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lumibird valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $257M | XXX | $244M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $152M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $45.1M | XXX | $36.1M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $23.6M | XXX | $17.3M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $13.3M | XXX | $6.6M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $90.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 3, 2025, Lumibird's stock price is EUR 16 (or $19).
Lumibird has current market cap of EUR 362M (or $421M), and EV of EUR 452M (or $525M).
See Lumibird trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $525M | $421M | XXX | XXX | XXX | XXX | $0.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 3, 2025, Lumibird has market cap of $421M and EV of $525M.
Lumibird's trades at 2.2x EV/Revenue multiple, and 14.5x EV/EBITDA.
Equity research analysts estimate Lumibird's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lumibird has a P/E ratio of 31.7x.
See valuation multiples for Lumibird and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $421M | XXX | $421M | XXX | XXX | XXX |
| EV (current) | $525M | XXX | $525M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.6x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | 22.2x | XXX | 30.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.7x | XXX | 63.6x | XXX | XXX | XXX |
| EV/FCF | 40.5x | XXX | 39.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLumibird's last 12 month revenue growth is 9%
Lumibird's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Lumibird's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lumibird's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lumibird and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lumibird acquired XXX companies to date.
Last acquisition by Lumibird was XXXXXXXX, XXXXX XXXXX XXXXXX . Lumibird acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Lumibird founded? | Lumibird was founded in 1970. |
| Where is Lumibird headquartered? | Lumibird is headquartered in France. |
| How many employees does Lumibird have? | As of today, Lumibird has 1.1K+ employees. |
| Who is the CEO of Lumibird? | Lumibird's CEO is Mr. Marc Le Flohic. |
| Is Lumibird publicy listed? | Yes, Lumibird is a public company listed on PAR. |
| What is the stock symbol of Lumibird? | Lumibird trades under LBIRD ticker. |
| When did Lumibird go public? | Lumibird went public in 1997. |
| Who are competitors of Lumibird? | Similar companies to Lumibird include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Lumibird? | Lumibird's current market cap is $421M |
| What is the current revenue of Lumibird? | Lumibird's last 12 months revenue is $257M. |
| What is the current revenue growth of Lumibird? | Lumibird revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Lumibird? | Current revenue multiple of Lumibird is 2.0x. |
| Is Lumibird profitable? | Yes, Lumibird is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lumibird? | Lumibird's last 12 months EBITDA is $45.1M. |
| What is Lumibird's EBITDA margin? | Lumibird's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Lumibird? | Current EBITDA multiple of Lumibird is 11.6x. |
| What is the current FCF of Lumibird? | Lumibird's last 12 months FCF is $13.0M. |
| What is Lumibird's FCF margin? | Lumibird's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Lumibird? | Current FCF multiple of Lumibird is 40.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
